Suzuki Hiroyuki

スズキヒロユキ | Suzuki Hiroyuki

Affiliation and department：
Job title： Associate Professor
Homepage URL (1)： http://www.md.tsukuba.ac.jp/epatho/

Research field (2)： Pharmacology , Experimental pathology

Research keywords (5)： Signal transduction , Transcription , Stem cell , TGF-beta , 実験病理学

Research theme for competitive and other funds (24)：

2022 - 2025 新規がん遺伝子THG-1の生体機能の解明と分子診断・治療法の開発
2019 - 2022 Role of THG-1 in squamous cell carcinoma development and its application to cancer therapy
2018 - 2020 新規のNrf2活性化メカニズムに着目した扁平上皮がん治療薬の探索
2017 - 2019 Master Regulator of squamous cell carcinoma TSC22D4/THG-1 and its application for medical development
2016 - 2019 Roles of THG-1 in squamous cell carcinoma development

Show all

Papers (142)：

Miu Hirose, Hiroyuki Suzuki, Rena Ubukata, Tomohiro Tanaka, Mika K Kaneko, Yukinari Kato. Development of specific anti-mouse atypical chemokine receptor 4 monoclonal antibodies. Biochemistry and biophysics reports. 2024. 40. 101824-101824
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, Takuro Nakamura, Miyuki Yanaka, Guanjie Li, Tomohiro Tanaka, Akira Ohkoshi, Manabu Kawada, Mika Kaneko, et al. Antitumor activities of anti-CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer. Oncology Reports. 2024. 52. 5
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, Guanjie Li, Tomohiro Tanaka, Manabu Kawada, Akira Ohkoshi, Mika K. Kaneko, Yukio Katori, Yukinari Kato. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas. International Journal of Molecular Sciences. 2024. 25. 17. 9190-9190
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, Mika K Kaneko, Yukinari Kato. Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab. International journal of molecular sciences. 2024. 25. 15
Rena Ubukata, Hiroyuki Suzuki, Tomohiro Tanaka, Guanjie Li, Mika K Kaneko, Yukinari Kato. Development of Sensitive Anti-Mouse CCR5 Monoclonal Antibodies Using the N-Terminal Peptide Immunization. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2024

ｍore...

MISC (1)：

七宮蓮, 鈴木裕之, 金子美華, 加藤幸成, 加藤幸成. Development of anti-HER2 monoclonal antibodies for gastric cancer. 日本癌学会学術総会抄録集(Web). 2022. 81st

Books (8)：

あなたのラボから薬を生み出すアカデミア創薬の実践 : all Japan体制の先端技術支援を利用した創薬の最前線
羊土社 2024 ISBN:9784758104166
がんゲノム医療時代の分子腫瘍学
文光堂 2022
TGF-β
2009
TGF-betaシグナル伝達系とがん治療
南山堂 2008
TGF-βシグナル伝達とがん治療
がんの分子標的治療 2008

ｍore...

Lectures and oral presentations (32)：

THG-1 overexpression stabilizes β-catenin via antagonizing NRBP1 in esophageal squamous cell carcinoma
(第79回日本癌学会学術総会 2020)
THG-1/TSC22D4による細胞老化の制御
(第79回日本癌学会学術総会 2020)
THG-1はHIF-1alphaの安定化を介して腫瘍の進行を促進する
(第3回がん三次元培養研究会 2019)
Regulation of c-MYC transcriptional activity by transforming growth factor-beta 1-stimulated clone 22
(第78回日本癌学会学術総会 2019)
Screening of macrocyclic peptide against CD44
(第78回日本癌学会学術総会 2019)

ｍore...

Education (3)：

- 2001 The University of Tokyo Graduate School, Division of Pharmaceutical Sciences
- 1998 The University of Tokyo Graduate School, Division of Pharmaceutical Sciences
- 1996 The University of Tokyo Faculty of Pharmaceutical Science

Professional career (1)：

博士(薬学) (東京大学)

Work history (5)：

2021/08 - 現在東北大学大学院医学系研究科分子薬理学分野准教授
2012/04/01 - 2021/07/31 筑波大学医学医療系准教授
2007/04/01 - 2012/03/31 筑波大学大学院人間総合科学研究科助教
2004/04/01 - 2007/03/31 筑波大学大学院人間総合科学研究科助手
2001/04/01 - 2004/03/31 日本学術振興会特別研究員PD

Awards (6)：

2012/11 - がん研究振興財団研究助成金
2008/12 - 安田記念医学財団若手癌研究助成
2007/11 - 武田科学振興財団武田科学振興財団薬学系研究奨励金
2007/02/11 - Nagoya International Cencer Treatment Symposium BMS Award in 2007
2006/03 - 上原記念生命科学財団上原記念生命科学財団研究奨励金

Show all

Association Membership(s) (5)：

日本薬理学会 , The Molecular Biology Society of Japan , THE JAPANESE SOCIETY OF PATHOLOGY , The Japanese Cancer Association , THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page